198 related articles for article (PubMed ID: 29417257)
1. Oncological effect of palliative transurethral resection of the prostate in patients with advanced prostate cancer: a propensity score matching study.
Choi SY; Ryu J; You D; Jeong IG; Hong JH; Ahn H; Kim CS
J Cancer Res Clin Oncol; 2018 Apr; 144(4):751-758. PubMed ID: 29417257
[TBL] [Abstract][Full Text] [Related]
2. Palliative Transurethral Resection of the Prostate in Patients with Metastatic Prostate Cancer: A Prospective Study of 188 Patients.
Qu M; Zhu F; Chen H; Lian B; Jia Z; Shi Z; Li J; Wang Y; Sun Y; Gao X
J Endourol; 2019 Jul; 33(7):570-575. PubMed ID: 31025578
[No Abstract] [Full Text] [Related]
3. [Efficacy and outcome of palliative TURP in patients with bladder outlet obstruction induced by advanced prostate cancer].
Liu L; Hou XF; Ma LL; Zhao L; Zhang HX
Beijing Da Xue Xue Bao Yi Xue Ban; 2015 Aug; 47(4):597-600. PubMed ID: 26284392
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Palliative Transurethral Resection of the Prostate on the Prognosis of Patients With Bladder Outlet Obstruction and Metastatic Prostate Cancer: A Population-Matched Study.
Fang K; Song P; Zhang J; Yang L; Liu P; Lu N; Dong Q
Front Surg; 2021; 8():726534. PubMed ID: 34778357
[No Abstract] [Full Text] [Related]
5. Palliative transurethral resection of the prostate: functional outcome and impact on survival.
Marszalek M; Ponholzer A; Rauchenwald M; Madersbacher S
BJU Int; 2007 Jan; 99(1):56-9. PubMed ID: 17034496
[TBL] [Abstract][Full Text] [Related]
6. Tumor cytoreduction results in better response to androgen ablation--a preliminary report of palliative transurethral resection of the prostate in metastatic hormone sensitive prostate cancer.
Qin XJ; Ma CG; Ye DW; Yao XD; Zhang SL; Dai B; Zhang HL; Shen YJ; Zhu Y; Zhu YP; Shi GH; Xiao WJ; Lin GW; Swanson GP
Urol Oncol; 2012; 30(2):145-9. PubMed ID: 20451424
[TBL] [Abstract][Full Text] [Related]
7. Transurethral resection of the prostate is an independent risk factor for biochemical recurrence after radical prostatectomy for prostate cancer.
Jin K; Qiu S; Liao XY; Zheng XN; Tu X; Tang LS; Yang L; Wei Q
Asian J Androl; 2020; 22(2):217-221. PubMed ID: 31210148
[TBL] [Abstract][Full Text] [Related]
8. Contemporary outcomes of palliative transurethral resection of the prostate in patients with locally advanced prostate cancer.
Pelletier J; Cyr SJ; Julien AS; Fradet Y; Lacombe L; Toren P
Urol Oncol; 2018 Aug; 36(8):363.e7-363.e11. PubMed ID: 29880461
[TBL] [Abstract][Full Text] [Related]
9. Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer.
Crain DS; Amling CL; Kane CJ
J Urol; 2004 Feb; 171(2 Pt 1):668-71. PubMed ID: 14713783
[TBL] [Abstract][Full Text] [Related]
10. Transurethral prostatic resection for acute urinary retention in patients with prostate cancer.
Chang CC; Kuo JY; Chen KK; Lin AT; Chang YH; Wu HH; Chang LS
J Chin Med Assoc; 2006 Jan; 69(1):21-5. PubMed ID: 16447922
[TBL] [Abstract][Full Text] [Related]
11. Can the need for palliative transurethral prostatic resection in patients with advanced carcinoma of the prostate be predicted?
Sehgal A; Mandhani A; Gupta N; Dubey D; Srivastava A; Kapoor R; Kumar A
J Endourol; 2005 Jun; 19(5):546-9. PubMed ID: 15989442
[TBL] [Abstract][Full Text] [Related]
12. [Risk factors for early castration-resistant prostate cancer after androgen deprivation therapy for bone-metastatic prostate cancer].
Huang FM; Li XH; Liang Y
Zhonghua Nan Ke Xue; 2018 Aug; 24(8):690-694. PubMed ID: 30173426
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer.
Kim M; Lee J; Jeong CW; Ku JH; Kim HH; Kwak C
Urol Oncol; 2015 May; 33(5):203.e1-9. PubMed ID: 25726498
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
15. The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment.
Ku JY; Lee JZ; Ha HK
Korean J Urol; 2015 Oct; 56(10):689-94. PubMed ID: 26495069
[TBL] [Abstract][Full Text] [Related]
16. Evolution and outcomes of 3 MHz high intensity focused ultrasound therapy for localized prostate cancer during 15 years.
Thüroff S; Chaussy C
J Urol; 2013 Aug; 190(2):702-10. PubMed ID: 23415962
[TBL] [Abstract][Full Text] [Related]
17. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study.
Heidenreich A; Pfister D; Porres D
J Urol; 2015 Mar; 193(3):832-8. PubMed ID: 25254935
[TBL] [Abstract][Full Text] [Related]
18. Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy.
Kadono Y; Nohara T; Ueno S; Izumi K; Kitagawa Y; Konaka H; Mizokami A; Onozawa M; Hinotsu S; Akaza H; Namiki M
World J Urol; 2016 Feb; 34(2):261-7. PubMed ID: 26047654
[TBL] [Abstract][Full Text] [Related]
19. The percent of positive biopsy cores improves prediction of prostate cancer-specific death in patients treated with dose-escalated radiotherapy.
Qian Y; Feng FY; Halverson S; Blas K; Sandler HM; Hamstra DA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e135-42. PubMed ID: 21345617
[TBL] [Abstract][Full Text] [Related]
20. Does transurethral resection of prostate (TURP) affect outcome in patients who subsequently develop prostate cancer?
D'Ambrosio DJ; Ruth K; Horwitz EM; Chen DY; Pollack A; Buyyounouski MK
Urology; 2008 May; 71(5):938-41. PubMed ID: 18279939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
